1. Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
- Author
-
Kana Ono, Hirotaka Ono, Yukihiro Toi, Jun Sugisaka, Mari Aso, Ryohei Saito, Sachiko Kawana, Tomoiki Aiba, Tetsuo Odaka, Suguru Matsuda, Shin Saito, Akane Narumi, Takahiro Ogasawara, Hisashi Shimizu, Yutaka Domeki, Keisuke Terayama, Yosuke Kawashima, Atsushi Nakamura, Shinsuke Yamanda, Yuichiro Kimura, Yoshihiro Honda, and Shunichi Sugawara
- Subjects
anti‐programmed cell death‐1 ,checkpoint inhibitor pneumonitis ,immune‐related adverse events ,non‐small cell lung cancer ,outcome ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The association between the development of checkpoint inhibitor pneumonitis (CIP) with tumor response and survival has remained unclear so far. The aim of the present study was to evaluate the association between CIP and the clinical efficacy of anti‐programmed cell death‐1 antibody in patients with advanced non‐small cell lung cancer (NSCLC). Methods Between January 2016 and August 2019, 203 advanced NSCLC patients were administered with nivolumab or pembrolizumab. Comparisons were made between patients with and without CIP. We evaluated the time‐to‐treatment failure (TTF), progression‐free survival (PFS), and overall survival (OS). Results CIP was observed in 28 (14%) patients. CIP was associated with a longer PFS (18.9 months [95% confidence interval, CI: 8.7 months–not reached] vs. 3.9 months [95% CI: 3.4–5.1 months, p
- Published
- 2021
- Full Text
- View/download PDF